{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-003665","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2022-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.498238+00:00","generated_at":"2026-06-26T22:48:35.065246+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"low","headline":"Ovid Therapeutics reduces workforce 20%, extends cash runway beyond 2024; OV329 on track for 2022 clinical entry","bullets":["Workforce reduced by ~20% to extend cash runway beyond 2024 as part of organizational restructuring.","OV329, a GABA aminotransferase inhibitor, expected to enter clinical trials in 2022 for tuberous sclerosis seizures.","Takeda to present pivotal Phase 3 soticlestat results in Dravet and Lennox-Gastaut syndromes in 2023.","Financial results for Q4/FY2021 reported but specific figures not provided in filing excerpt; focus on cost reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-003665","json":"https://secwatch.observer/filing/0000950170-22-003665.json","markdown":"https://secwatch.observer/filing/0000950170-22-003665.md","text":"https://secwatch.observer/filing/0000950170-22-003665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000095017022003665/0000950170-22-003665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000095017022003665/ovid-20220315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:48:35.065246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}